by Paul | 25 June 2026 | News
Top line data readout expected in late Q3/early Q4 INFORM-MS trial is a randomized, double-blind, placebo-controlled Phase 2a trial using Intranasal Foralumab in patients with Non-Active Secondary Progressive Multiple Sclerosis BOSTON, MA, June 25, 2026 – Tiziana Life...
by Paul | 14 May 2026 | News
Foralumab is the first intranasal immune modulator in clinical trials for patients with Multiple System Atrophy BOSTON, MA, May 14, 2026 – Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana”), a biotechnology company developing its lead candidate, intranasal...
by Paul | 25 February 2026 | News
BOSTON, MA, February 25, 2026 – Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana”), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, announces positive new biomarker data from a late-breaking...
by Paul | 9 January 2026 | News
BOSTON, MA, January 9, 2026 – Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana”), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, announces that Chief Executive Officer Ivor Elrifi will...
by Paul | 17 December 2025 | News
First Patient Dosed with Intranasal Foralumab in Randomized, Placebo-Controlled Phase 2 Trial Builds on Recent Evidence of Persistent Neuroinflammation in Alzheimer’s Patients Treated with Anti-Amyloid Therapies BOSTON, MA, December 17, 2025 – Tiziana Life Sciences,...
by Paul | 12 December 2025 | News
First Patient Expected to be Dosed Next Week with Intranasal Foralumab PET Scan Shows Presence of Untreated Neuroinflammation in Alzheimer’s Patient on Leqembi® (Lecanemab) Anti-Amyloid Therapy BOSTON, MA, December 12, 2025 – Tiziana Life Sciences, Ltd. (Nasdaq:...
by Paul | 14 August 2025 | News
BOSTON, MA, August 14, 2025 – Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3...
by Paul | 13 June 2025 | News
NEW YORK, June 13, 2025 – Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal...
by Paul | 23 April 2025 | News
NEW YORK, April 23, 2025 – Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal...
by Paul | 2 April 2025 | News
NEW YORK, April 2, 2025 – Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal...
by Paul | 25 March 2025 | News
NEW YORK, March 25, 2025 – Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal...
